Clinical trial
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
NCT00216723 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 30, 2004
- Completion date
- December 31, 2009
- Enrollment
- 3,000 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.